Atrial Fibrillation – Landscape And Forecast – Disease Landscape & Forecast
Copy/Paste the core content from the latest edited report brochure. DELETE the “Market Outlook” header from the top.
Atrial fibrillation (AF) is an abnormal heart rhythm characterized by rapid and irregular beats of the atrial chambers of the heart. AF is the most common arrhythmia treated in clinical practice. Pharmacological treatment includes rate control therapy (e.g., beta blockers, calcium channel blockers, digoxin) and anticoagulation therapy (e.g., vitamin K antagonists, direct-acting oral anticoagulants [DOACs]). Novel agents being investigated in clinical trials to treat AF include Anthos Therapeutics’ abelacimab, Bayer’s asundexian, Janssen’s milvexian, and ARCA’s bucindolol. We expect some of these drugs to launch during our forecast period and fulfill some of the unmet needs that remain in AF. Unmet needs include superior efficacy and safety / tolerability of antiarrythmic drugs, as bradycardia is an important safety concern in AF patients, and superior safety of anticoagulant drugs for stroke prevention in AF.
Questions answered
- What do key opinion leaders think about emerging therapies such as Anthos Therapeutics’ abelacimab, Bayer’s asundexian, Janssen’s milvexian, and ARCA’s bucindolol? How will emerging therapies differentiate themselves in an increasingly crowded market?
- What are the key treatment drivers and goals within AF? How do current therapies perform on these goals?
- What are the key unmet needs in AF, and how likely are they to be met?
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancements
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Atrial Fibrillation - Landscape And Forecast - Disease Landscape & Forecast
- Key Findings
- Atrial Fibrillation Key Findings - October 2023
- Key Updates
- October 2023
- Market Outlook
- Key findings
- Market share of drug classes for atrial fibrillation: 2022
- Market share of drug classes for atrial fibrillation: 2032
- Atrial fibrillation SWOT analysis
- Market drivers and constraints
- What factors are driving the market for atrial fibrillation?
- What factors are constraining the market for atrial fibrillation?
- Annual atrial fibrillation sales by drug class in the major pharmaceutical markets: 2022-2032
- Annual atrial fibrillation sales by segment in the major pharmaceutical markets: 2022-2032
- Drug-type-specific trends
- Annual patient share of stroke prevention therapies in atrial fibrillation in the major markets: 2022-2032
- Annual sales of stroke prevention therapies in atrial fibrillation in the major markets: 2022-2032
- Annual patient share of rate control therapies in atrial fibrillation in the major markets: 2022-2032
- Annual patient share of chronic rhythm control therapies in atrial fibrillation in the major markets: 2022-2032
- Annual patient share of cardioversion drugs in atrial fibrillation in the major markets: 2022-2032
- Annual sales of rate and rhythm control drugs in atrial fibrillation in the major markets: 2022-2032
- Key findings
- Forecast
- Market Forecast Assumptions
- Market Forecast Dashboard
- Etiology and Pathophysiology
- Disease overview
- Etiology
- Risk factors for atrial fibrillation
- Major clinical manifestations and diagnosis of atrial fibrillation
- Classification of atrial fibrillation and disease progression
- Classification of atrial fibrillation
- Pathophysiology
- The cardiac conduction system
- Phases and ionic currents of the human cardiac action potential
- Comparison of ECG recordings from healthy and atrial fibrillation patients
- Factors contributing to atrial fibrillation
- Electrical remodeling
- Structural remodeling
- Contractile remodeling
- Neural / autonomic remodeling
- Role of inflammation in atrial fibrillation
- Role of genetics in atrial fibrillation
- Key pathways and drug targets
- Atrial fibrillation key drug targets and rationale
- Disease overview
- Epidemiology
- Key findings
- Epidemiology populations
- Diagnosed Atrial Fibrillation prevalent cases: 2022-2032
- Disease definition, methods, and sources used
- Total atrial fibrillation prevalent cases: 2022-2032
- Disease definition, methods, and sources used
- Diagnosed atrial fibrillation prevalent cases by subtype: 2022-2032
- Drug-treated cases of atrial fibrillation: 2022-2032
- Key findings
- Current Treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for atrial fibrillation
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for atrial fibrillation
- Current treatments used for atrial fibrillation
- Market events impacting the use of key current therapies for atrial fibrillation
- Advantages and disadvantages of vitamin K antagonists
- Expert insight: vitamin K antagonists
- Advantages and disadvantages of dabigatran etexilate mesylate
- Key results from select clinical trials investigating dabigatran etexilate mesylate for the treatment of atrial fibrillation
- Expert insight: dabigatran etexilate mesylate
- Advantages and disadvantages of rivaroxaban
- Key results from select clinical trials investigating rivaroxaban for the treatment of atrial fibrillation
- Ongoing clinical development of rivaroxaban
- Expert insight: rivaroxaban
- Advantages and disadvantages of apixaban
- Key results from select clinical trials investigating apixaban for the treatment of atrial fibrillation
- Ongoing clinical development of apixaban
- Key ongoing clinical trials of apixaban in the treatment of atrial fibrillation
- Expert insight: apixaban
- Advantages and disadvantages of edoxaban
- Key results from select clinical trials investigating edoxaban for the treatment of atrial fibrillation
- Ongoing clinical development of edoxaban
- Key ongoing clinical trials of edoxaban in the treatment of atrial fibrillation
- Expert insight: edoxaban
- Advantages and disadvantages of beta blockers
- Expert insight: beta blockers
- Advantages and disadvantages of non-dihydropyridine calcium channel blockers
- Key results from select clinical trials investigating non-dihydropyridine calcium channel blockers for the treatment of atrial fibrillation
- Expert insight: non-dihydropyridine calcium channel blockers
- Advantages and disadvantages of digitalis glycosides
- Key results from select clinical trials investigating digitalis glycosides for the treatment of atrial fibrillation
- Expert insight: digitalis glycosides
- Class Ic antiarrhythmics
- Class III antiarrhythmics
- Advantages and disadvantages of class Ic antiarrhythmics
- Advantages and disadvantages of class III antiarrhythmics
- Key results from select clinical trials investigating class Ic and class III antiarrhythmics for the treatment of atrial fibrillation
- Expert insight: class Ic antiarrhythmics
- Expert insight: class III antiarrhythmics
- Advantages and disadvantages of antiplatelet therapies
- Ongoing clinical development of antiplatelet therapies
- Key ongoing clinical trials of antiplatelet agents in the treatment of atrial fibrillation
- Expert insight: antiplatelet therapies
- Medical practice
- Overview
- Factors influencing drug selection in atrial fibrillation
- Anticoagulation treatment decision tree for atrial fibrillation
- Treatment decision tree for atrial fibrillation: United States
- Treatment decision tree for atrial fibrillation: Europe
- Treatment decision tree for atrial fibrillation: Japan
- Key findings
- Unmet Need Overview
- Current and future attainment of unmet needs in atrial fibrillation
- Top unmet needs in atrial fibrillation: current and future attainment
- Expert insight: unmet need in atrial fibrillation
- Drug Pipeline
- Pipeline
- Regulatory milestones
- Indication comparison
- Emerging Therapies
- Key findings
- Key emerging therapies
- Key therapies in development for atrial fibrillation
- Estimated launch dates of key emerging therapies for the treatment of atrial fibrillation
- Key results of select clinical trials investigating abelacimab for the treatment of atrial fibrillation
- Key ongoing clinical trials of abelacimab in the treatment of atrial fibrillation
- Analysis of the clinical development program for abelacimab
- Expert insight: abelacimab
- Expectations for launch and sales opportunity of abelacimab in atrial fibrillation
- Key results of select clinical trials investigating asundexian for the treatment of atrial fibrillation
- Key ongoing clinical trials of asundexian in the treatment of atrial fibrillation
- Analysis of the clinical development program for asundexian
- Expert insight: asundexian
- Expectations for launch and sales opportunity of asundexian in atrial fibrillation
- Key ongoing clinical trials of milvexian in the treatment of atrial fibrillation
- Analysis of the clinical development program for milvexian
- Expert insight: milvexian
- Expectations for launch and sales opportunity of milvexian in atrial fibrillation
- Key results of select clinical trials investigating Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation
- Analysis of the clinical development program for Gencaro (bucindolol hydrochloride)
- Expert insight: Gencaro (bucindolol hydrochloride)
- Expectations for launch and sales opportunity of Gencaro (bucindolol hydrochloride) in atrial fibrillation
- Early-phase pipeline analysis
- Select compounds in early-phase development for atrial fibrillation
- Key discontinuations and failures in atrial fibrillation
- Key discontinuations and failures
- Expert insight: key discontinuations and failures
- Key findings
- Access & Reimbursement Overview
- Region-specific reimbursement practices
- Key market access considerations in atrial fibrillation: United States
- General reimbursement environment: United States
- Key market access considerations in atrial fibrillation: EU5
- General reimbursement environment: EU5
- Key market access considerations in atrial fibrillation: Japan
- General reimbursement environment: Japan
- Region-specific reimbursement practices
- Appendix
- Abbreviations
- Atrial fibrillation bibliography
- Key Findings
Laia Martínez-Carreres, M.Sc., Ph.D., Healthcare Research & Data Analyst, Cardiovascular, Metabolic, Renal, and Hematological Disorders. Dr. Martinez-Carreres has authored reports on polycystic kidney disease, venous thromboembolism, and atrial fibrillation. Prior to joining Clarivate, she was a clinical research project manager at Parc Taulí Hospital (Spain). She holds a Ph.D. in biomedical sciences from the University of Lausanne, where she studied the role of the cell cycle-related protein CDK4 in metabolism in the laboratory of Professor Lluis Fajas. She also holds a master’s degree in translational medicine and a bachelor’s degree in biomedical sciences, both from the University of Barcelona. Dr. Martínez-Carreres also trained as a data analyst at EADA Business School in Spain.